Skip to main content

Table 1 Clinical characteristics, treatment, and outcome of six patients with HHT treated with topical propranolol for epistaxis

From: Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report

Pt. no. Demographics & HHT features Topical propranolol treatment -- duration and outcome measures
Age/ gender (M/F) HHT mutation Other HHT features Treatment duration (wks) ESS before/ after 12 wks treatment Hb (gr%) before/after 12 wks treatment PC before treatment/after 12 wks/after 24 wks
1 72/M Endoglin PAVMs, GI bleed 48 7.3/1.5 7.4/10.9 10/3/0
2 55/F Endoglin HAVMs, GI bleed 12 4.4/1.9 12/12
3 68/F ACVRL-1 PAVMs, HAVMs 38 10/5.9 5.4/9.9 9/6/0
4 41/M ACVRL-1 PAVMs 34 4.4/2.5 12.5/14
5 37/F ACVRL-1 None 26 6.2/4.2 6.1/10
6 76/F Not done HAVMs 26 6.4/4.9 7.1/9.1 8/6/2
p    0.028a 0.043a 0.109a (12 weeks) 0.109a (24 weeks)
  1. aWilcoxon signed-rank test
  2. Abbreviations: ESS epistaxis severity score, GI gastrointestinal, HAVMs hepatic arteriovenous malformations, Hb hemoglobin, PAVMs pulmonary arteriovenous malformations, PC packed red cells